Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome


ERDOĞAN M. , KARADENİZ M., Alper G. , TAMSEL S. , ULUER H. , Caglayan O., ...Daha Fazla

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, cilt.116, ss.143-147, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 116 Konu: 3
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1055/s-2007-992118
  • Dergi Adı: EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
  • Sayfa Sayıları: ss.143-147

Özet

Objective: We aimed to assess circulating thrombin activatable fibrinolysis inhibitor (TAFI) levels and carotid intima-media thickness (CIMT) in PCOS patients and control sujects. in this study we aimed to evaluate the relation between the levels of TAFI and homocysteine, high sensitive CRP (hsCRP), fibrinogen and CIMT in PCOS patients carrying a potential risk for developing CVD and diabetes and compared with age- and body mass index-matched controls.